New Delhi, Oct. 3 -- On 25 September, US President Donald Trump announced a 100% tariff on imports of branded or patented pharmaceutical products starting 1 October. The tariff aims to boost US domestic pharmaceutical manufacturing and reduce its reliance on imports. It applies across the board, unless the pharmaceutical company is building a manufacturing plant in the United States and has at least broken ground.

In this article we discuss three Indian pharma stocks that have been affected by the news. We wish to emphasise that this is not an analysis of the nature of impact, since the details are unclear. For example, does it exempt companies that already have a manufacturing plant in the US? Are complex generics included?

All we are ...